Merck Discontinues BELLWAVE-011 Phase 3 Trial for Nemtabrutinib
Merck halts Phase 3 BELLWAVE-011 for nemtabrutinib after an external DMC finds risk-benefit balance unfavorable, closing a late-stage BTK inhibitor program.


An external Data Monitoring Committee's unfavorable risk-benefit assessment has effectively ended Merck's Phase 3 BELLWAVE-011 trial for nemtabrutinib, the company's investigational BTK inhibitor targeting blood cancers, a decision that carries direct consequences for any contract manufacturing organizations and clinical supply chains aligned to the program.
DMC-driven discontinuations at Phase 3 represent one of the more consequential late-stage failure modes in oncology development. Unlike regulatory holds or voluntary pauses, an independent committee's determination that projected benefit no longer justifies patient risk typically forecloses resumption. For development teams running parallel BELLWAVE studies, the signal warrants immediate review of shared protocol assumptions and any bridging data strategies built around nemtabrutinib's efficacy profile.
The BTK inhibitor class has faced intensifying scrutiny as second- and third-generation candidates attempt to differentiate on tolerability and resistance profiles against established agents. Nemtabrutinib's discontinuation adds to a pattern of late-stage attrition in this space, reinforcing that favorable early-phase data does not reliably predict Phase 3 DMC outcomes, a point relevant to portfolio risk modeling across the sector.
For QA directors and regulatory affairs leads involved in oncology CMC, the discontinuation also surfaces a practical checkpoint: investigational product manufactured under 21 CFR Part 211 GMP conditions for BELLWAVE-011 will require disposition decisions, and any process validation work scoped specifically to nemtabrutinib's commercial pathway will need to be formally closed out within the quality management system under ICH Q10 lifecycle principles.
Merck has not indicated whether nemtabrutinib development will continue under a revised protocol or alternative indication, leaving pipeline sequencing and any partnered manufacturing commitments in an indeterminate state pending further disclosure.
Source: Media4Growth via Indian Pharma Post, 17 November 2026.

Reporting on the science, business and regulation shaping the pharmaceutical industry.
More from Pharma News
All stories →
EktaH Advances NKS-3 Obesity Drug into Phase IIa After Securing €2.4 Million Funding

Innate Pharma Achieves Phase 1 Milestone for IPH4502 ADC with Linker Stability Signal

Discussion